

Attorney Docket No. 14509-C2 RI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)
U.S. Patent No. 5,637,310)
Randall K. JOHNSON) Group Art Unit: Unassigned
Reissue Serial No.: Unassigned) Examiner: Unassigned
Filed: Herewith)
For: METHOD OF TREATING PROSTATIC)
ADENOCARCINOMA)

BOX REISSUE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

REISSUE DECLARATION UNDER 37 C.F.R. § 1.175

I, Randall K. Johnson, with the citizenship, residence, and post office address as listed below, do hereby state and declare as follows:

1. I believe I am the original sole inventor of the subject matter which is described and claimed in United States Patent No. 5,637,310, granted on June 10, 1997, and for which a reissue patent is sought on the invention entitled, "Method of Treating Prostatic Adenocarcinoma."

2. I hereby state that I have reviewed and understand the contents of the above-identified patent.

**Reissue Application of
Patent No. 5,785,994
Atty. Docket No. 14509-C2 RI**

3. I acknowledge the duty to disclose information that is material to the patentability of this reissue application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

4. I believe that U.S. Patent No. 5,637,310 is at least partially inoperative or invalid because, without any deceptive intention, we claimed more or less than we had the right to claim in the patent.

5. An error which is a statutory basis for reissue is that while as issued, the '310 patent correctly stated that it is a continuation of application Serial No. 08/170,481, filed December 20, 1993, now U.S. Patent No. 5,496,556 ("the '556 patent"), it omitted citation of the fact that the '556 patent itself was a continuation of application Serial No. 07/544,709, filed June 27, 1990, now U.S. Pat. No. 5,300,294 ("the '294 patent"). The purpose of this reissue application is to claim priority for the '310 patent back to original application Serial No. 544,709 which led to the '294 patent, and to thereby obtain the benefit of the June 27, 1990 filing date of the '294 patent.

6. The above-described error and all other errors corrected in this reissue application arose without any deceptive intent.


7. I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided

Reissue Application of
Patent No. 5,785,994
Atty. Docket No. 14509-C2 RI

by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
08/170,481	December 20, 1993	U.S. Patent No. 5,496,556
07/544,709	June 27, 1990	U.S. Patent No. 5,300,294

8. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First Inventor Randall Keith Johnson	Inventor's Signature 	Date 13 SEPT 01
Residence 71 Lianfair Circle, Ardmore, Pennsylvania 19003	Citizenship United States	
Post Office Address GlaxoSmithKline Corporate Intellectual Property-UW 2220 79 Swedeland Road King of Prussia, PA 19406		

Attorney Docket No. 14509-C2 RI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)
U.S. Patent No. 5,637,310)
)
Randall K. JOHNSON) Group Art Unit: Unassigned
)
Reissue Serial No.: Unassigned) Examiner: Unassigned
)
Filed: Herewith)
)
For: METHOD OF TREATING PROSTATIC)
ADENOCARCINOMA)

BOX REISSUE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

CONSENT OF ASSIGNEE, OFFER TO SURRENDER
ORIGINAL PATENT, AND STATEMENT UNDER 37 C.F.R. § 3.73(b)

U.S. Patent No. 5,637,310 is assigned to SmithKline Beecham Corporation as assignee of the entire right, title and interest in said patent by virtue of an assignment recorded at Reel 5377, Frames 499 and 500 on July 12, 1990.

SmithKline Beecham Corporation hereby consents to the accompanying application for reissue of U.S. Patent 5,637,310.


SmithKline Beecham Corporation hereby offers to surrender U.S. Patent 5,637,310, when the reissue application is otherwise in condition for allowance.

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of the assignee.

Reissue Application of
U.S. Patent No. 5,637,310
Atty. Docket No. 14509-C2 RI

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

September 13, 2001
Date



The image shows a handwritten signature in black ink. The signature consists of several fluid, sweeping strokes that form the letters 'S', 't', 'e', 'p', 'h', 'e', 'n', ' ', 'V', 'e', 'n', 'e', 't', 'i', 'a', 'n', 'e', 'r'. Below the signature, the word 'Signature' is printed in a small, sans-serif font.

Stephen Venetianer

Vice President/Director Pharmaceuticals

Attorney Docket No. 14509-C2 RI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)	
U.S. Patent No. 5,637,310)	
)	
Randall K. JOHNSON)	Group Art Unit: Unassigned
)	
Reissue Serial No.: Unassigned)	Examiner: Unassigned
)	
Filed: Herewith)	
)	
For: METHOD OF TREATING PROSTATIC)	
ADENOCARCINOMA)	

BOX REISSUE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

POWER OF ATTORNEY
AND STATEMENT UNDER 37 C.F.R. § 3.73(b)

U.S. Patent No. 5,637,310 is assigned to SmithKline Beecham Corporation as assignee of the entire right, title and interest in said patent by virtue of an assignment recorded at Reel 5377, Frames 499 and 500 on July 12, 1990.

SmithKline Beecham Corporation hereby appoints as attorney at least one of the following, both jointly and separately, as its attorneys with full power of substitution and revocation to prosecute this application for reissue, to receive the reissued Letters Patent, and to transact all business in the Patent and Trademark Office connected therewith: Wayne J. Dustman, Reg. No. 33,870; Stephen Venetianer, Reg. No. 25,659; Jerry D. Voight, Reg. No. 23,020; Herbert H. Mintz, Reg. No. 26,691; Barbara C. McCurdy, Reg. No. 32,120; Charles E.

Reissue Application of
U.S. Patent No. 5,637,310
Atty. Docket No. 14509-C2 RI


Van Horn, Reg. No. 40,266; and Lara C. Kelley, Reg. No. 41,551. Please send all future correspondence concerning this application to SmithKline Beecham Corporation at the following address:

Wayne J. Dustman, Esq.
GlaxoSmithKline
Corporate Intellectual Property-UW2220
709 Swedeland Road
King of Prussia, PA 19406-0939

The undersigned, whose title is supplied below, is empowered to sign on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

September 13, 2001
Date



Stephen Venetianer
Vice President/Director, Pharmaceuticals